Definium Therapeutics reported an insider sale by Chief Executive Officer Robert Barrow on March 25, 2026, when he disposed of 24,431 shares of common stock for approximately $451,240. The shares were sold at weighted average prices ranging from $18.36 to $18.80. At the time of the transaction the company stock was trading near its 52-week high of $19.67, following a 188% increase over the prior year.
Following the disposition, Barrow retains direct ownership of 752,454 shares. That total includes 1,586 shares that were acquired through the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan. The company disclosed that the sales were made to satisfy withholding tax obligations tied to the settlement of vested restricted stock units. The action was carried out under a Rule 10b5-1 trading plan that Barrow adopted on June 15, 2022.
In related corporate disclosures, Definium Therapeutics released its financial results for the fourth quarter of 2025. The company highlighted substantial investments in research and development during the period and called out its DT120 program as a notable area of focus within its broader clinical strategy. The quarterly report showed a significant net loss for the quarter, but management also reported a strong cash position that the company says supports its clinical pipeline.
The company emphasized its continued commitment to R&D spending as part of efforts to advance its projects and build research capabilities. The earnings commentary did not provide specific revenue figures for the quarter. The focus on R&D investment and the mention of a solid cash cushion were presented as elements underpinning the companys strategic push to progress its clinical offerings.
Taken together, the disclosed insider sale and the quarterly financial update provide a snapshot of current activity at Definium: an executive stock sale for tax-related reasons and a corporate posture centered on funding and advancing clinical programs. The filings and disclosures leave certain financial details, such as explicit revenue numbers, unreported in the public commentary accompanying the earnings release.
Clear summary
Robert Barrow sold 24,431 shares on March 25, 2026, for roughly $451,240 at weighted average prices of $18.36 to $18.80 under a Rule 10b5-1 plan to satisfy withholding tax obligations. After the sale he owns 752,454 shares, including 1,586 from the 2024 Employee Share Purchase Plan. Separately, Definium reported Q4 2025 results showing significant R&D investment, focus on the DT120 program, a sizable net loss, and a strong cash position. Revenue figures were not specified in the earnings commentary.